Levanz 25mg Tablet contains Levosulpiride, a selective dopamine D2 receptor antagonist primarily used in the treatment of gastrointestinal disorders and certain psychiatric conditions. It is indicated for managing symptoms associated with functional dyspepsia, gastroesophageal reflux disease (GERD), and diabetic gastroparesis by enhancing gastric motility and accelerating gastric emptying. Additionally, Levanz 25mg is employed in the treatment of schizophrenia and other psychotic disorders due to its antipsychotic properties. The drug exerts its therapeutic effects by modulating dopaminergic transmission in the central nervous system and the gastrointestinal tract, thereby improving gastrointestinal motility and alleviating psychotic symptoms. Levanz 25mg Tablet is generally well-tolerated; however, potential side effects may include extrapyramidal symptoms, hyperprolactinemia, sedation, and gastrointestinal disturbances such as nausea or diarrhea. It is contraindicated in patients with hypersensitivity to Levosulpiride, prolactin-dependent tumors, or severe renal impairment. Caution is advised when administering to patients with a history of seizures or cardiovascular disorders. Dosage should be individualized based on the clinical condition and response, and it is recommended to follow prescribing guidelines strictly. Regular monitoring by a healthcare professional is essential to ensure efficacy and minimize adverse effects during therapy with Levanz 25mg Tablet.